Skip to main content
SpringerLink
Log in

The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis

  • Meta-Analysis
  • Published:
Endocrine Aims and scope Submit manuscript

Abstract

Cinacalcet, the first calcimimetic to be approved for the treatment of secondary hyperparathyroidism (SHPT) in the chronic kidney disease patients, offers a novel therapeutic approach to SHPT. The aim of this meta-analysis is to access the efficacy and safety of cinacalcet on bone and mineral metabolism disorders in the dialysis patients with SHPT. Randomized controlled trials on cinacalcet combined with vitamin D and/or phosphate binders in the dialysis patients with SHPT were identified in Pubmed, Sciencedirect, and the Cochrane library. Data were analyzed with RevMan software. We compared the proportion of patients achieving the biochemical targets recommended by the Kidney Disease Outcomes Quality Initiative (KDOQI) guidelines and the incidence of adverse events between the cinacalcet and control groups. Six trials involving 2,548 patients were included. A greater proportion of patients in the cinacalcet group compared with the conventional group achieved the KDOQI targets. The relative risks (RRs) were parathyroid hormone (PTH) (RR = 3.51, 95 % CI: 2.38–5.17), calcium (RR = 2.04, 95 % CI: 1.76–2.37), phosphorus (RR = 1.15, 95 % CI: 0.83–1.60), and calcium–phosphorus product (Ca × P) (RR = 1.41, 95 % CI: 1.18–1.69), the number of patients simultaneously achieving the KDOQI targets for PTH + Ca × P was also greater (RR = 3.89, 95 % CI: 2.36–6.41), with p < 0.001 for each. The most common adverse events were nausea, vomiting, diarrhea, and hypocalcemia, which had a higher incidence in the cinacalcet group, but were usually mild to moderate in severity and transient. Compared with conventional therapy, treatment with cinacalcet results in more patients achieving KDOQI targets and offers an effective and safety therapeutic option for controlling mineral and bone disorders in the dialysis patients with SHPT.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. T. Shigematsu, T. Akizawa, E. Uchida, Y. Tsukamoto, M. Lwasaki, S. Koshikawa, Long-term cinacalcet HCl treatment improved bone metabolism in Japanese hemodialysis patients with secondary hyperparathyroidism. Am. J. Nephrol. 29, 230–236 (2009)

    Article  PubMed  CAS  Google Scholar 

  2. M. Chonchol, F. Locatelli, H.E. Abboud, C. Charytan, A.L.M. de Francisco, S. Jolly et al., A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am. J. Kidney Dis. 53(2), 197–207 (2009)

    Article  PubMed  CAS  Google Scholar 

  3. G.A. Block, P.S. Klassen, J.M. Lazarus, N. Ofsthun, E.G. Lowrie, G.M. Chertow, Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J. Am. Soc. Nephrol. 15, 2208–2218 (2004)

    Article  PubMed  CAS  Google Scholar 

  4. E.W. Young, J.M. Albert, S. Satayathum, D.A. Goodkin, R.L. Pisoni, T. Akiba et al., Predictors and consequences of altered mineral metabolism: the dialysis outcomes and practice patterns study. Kidney Int. 67, 1179–1187 (2005)

    Article  PubMed  CAS  Google Scholar 

  5. S.C. Verberckmoes, V. Persy, G.J. Behets, E. Neven, A. Hufkens, H. Zebger-Gong et al., Uremia-related vascular calcification: more than apatite deposition. Kidney Int. 71, 298–303 (2007)

    Article  PubMed  CAS  Google Scholar 

  6. G.M. Chertow, Z.J. Lu, X. Xu, T.G. Knight, W.G. Goodman, D.A. Bushinsky et al., Self-reported symptoms in patients on hemodialysis with moderate to severe secondary hyperparathyroidism receiving combined therapy with cinacalcet and low-dose vitamin D sterols. Hemodial. Int. (2011). doi:10.1111/j.1542-4758.2011.00642.x

    Google Scholar 

  7. L. Lucchi, C. Carboni, L. Stipo, V. Malaguti, F. Ferrari, K. Graziani et al., Early initiation of cinacalcet for the treatment of secondary hyperparathyroidism in hemodialysis patients: a three-year clinical experience. Artif. Organs 35(12), 1186–1193 (2011)

    Article  PubMed  CAS  Google Scholar 

  8. P. Urena, S.H. Jacobson, E. Zitt, M. Vervloet, F. Malberti, N. Ashman et al., Cinacalcet and achievement of the NKF/K-DOQI recommended target values for bone and mineral metabolism in real-world clinical practice- the ECHO observational study. Nephrol. Dial. Transplant. 24, 2852–2859 (2009)

    Article  PubMed  CAS  Google Scholar 

  9. National Kidney Foundation, K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am. J. Kidney Dis. 42(suppl 4), S1–S202 (2003)

    Google Scholar 

  10. M.D. Danese, V. Belozeroff, K. Smirnakis, K.J. Rothman, Consistent control of mineral and bone disorder in incident hemodialysis patients. Clin. J. Am. Soc. Nephrol. 3, 1423–1429 (2008)

    Article  PubMed  Google Scholar 

  11. D. Fouque, H. Roth, G. London et al., Achieving K/DOQI targets for phosphorus and calcium metabolism by dialysis modality among prevalent ESRD patients in France in 2006. The French prospective phosphorus and calcium observatory in maintenance dialysis (abstract). J. Am. Soc. Nephrol. 18, 9 (2007)

    Google Scholar 

  12. A.J. Brown, Vitamin D analogs for secondary hyperparathyroidism: what does the future hold? J. Steroid Biochem. Mol. Biol. 103, 578–583 (2007)

    Article  PubMed  CAS  Google Scholar 

  13. W. Seeherunvong, O. Nwobi, C.L. Abitbol, J. Chandar, J. Strauss, G. Zilleruelo, Paricalcitol versus calcitriol treatment for hyperparathyroidism in pediatric hemodialysis patient. Pediatr. Nephrol. 21, 1434–1439 (2006)

    Article  PubMed  Google Scholar 

  14. L. Greenbaum, R. Grenda, P. Qiu, I. Restaino, A. Wojtak, A. Paredes et al., Intravenous calcitriol for treatment of hyperparathyroidism in children on hemodialysis. Pediatr. Nephrol. 20, 622–630 (2005)

    Article  PubMed  Google Scholar 

  15. E. Zitt, C. Jager, A.R. Rosenkranz, M. Eigner, K. Kodras, J. Kovarik et al., Effective use of cinacalcet for the treatment of secondary hyperparathyroidism in Austrian dialysis patients-results of the Austrian cohort of the ECHO study. Wien. Klin. Wochenschr. 123, 45–52 (2011)

    Article  PubMed  CAS  Google Scholar 

  16. E.F. Nemeth, M.E. Steffey, L.G. Hammerland, B.C.P. Hung, B.C. VanWagenen, E.G. DelMar et al., Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl Acad. Sci. U S A 95, 4040–4045 (1998)

    Article  PubMed  CAS  Google Scholar 

  17. Nobuo. Nagano, Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 109, 339–365 (2006)

    Article  PubMed  CAS  Google Scholar 

  18. J. Cunningham, M. Danese, K. Olson, P. Classen, G.M. Chertow, Effects of the calcimimetic cinacalcet HCl on cardiovascular disease, fracture, and health-related quality of life in secondary hyperparathyroidism. Kidney Int. 68, 1793–1800 (2005)

    Article  PubMed  CAS  Google Scholar 

  19. M. Ketteler, K.J. Martin, M. Cozzolino, D. Goldsmith, A. Sharma, S. Khan et al., Paricalcitol versus cinacalcet plus low-dose vitamin D for the treatment of secondary hyperparathyroidism in patients receiving haemodialysis: study and baseline characteristics of the IMPACT SHPT study. Nephrol. Dial. Transplant. 0, 1–8 (2011)

    Google Scholar 

  20. Kidney Disease: Improving Global Outcomes, KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int. Suppl 76(Suppl 113), S1–S130 (2009)

    Google Scholar 

  21. K. Uhlig, J.S. Berns, B. Kestenbaum, R. Kumar, M.B. Leonard, K.J. Martin et al., KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-mineral and bone disorder (CKD-MBD). Am. J. Kidney Dis. 55, 773–799 (2010)

    Article  PubMed  Google Scholar 

  22. S.M. Moe, G.M. Chertow, J.W. Coburn, L.D. Quarles, W.G. Goodman, G.A. Block et al., Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 67, 760–771 (2005)

    Article  PubMed  CAS  Google Scholar 

  23. J.S. Lindberg, B. Culleton, G. Wong, M.F. Borah et al., Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 16, 800–807 (2005)

    Article  PubMed  CAS  Google Scholar 

  24. J.R. Sterrett, J. Strom, H.K. Stummovoll, U. Bahner, A. Disney, S.D. Soroka et al., Cinacalcet HCl (Sensipar/Mimpara) is an effective chronic therapy for hemodialysis patients with secondary hyperparathyroidism. Clin. Nephrol. 68(1), 10–17 (2007)

    PubMed  CAS  Google Scholar 

  25. P. Messa, F. Macário, M. Yaqoob, K. Bouman, J. Braun, B. Albertini et al., The OPTIMA study: assessing a new cinacalcet (Sensipar/Mimpara) treatment algorithm for secondary hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 3, 36–45 (2008)

    Article  PubMed  CAS  Google Scholar 

  26. S. Fishbane, W.B. Shapiro, D.B. Corry, S.L. Vicks, M. Roppolo, K. Rappaport et al., Cinacalcet HCl and concurrent low-dose vitamin D improves treatment of secondary hyperparathyrodism in dialysis patients compared with vitamin D alone: the ACHIEVE study results. Clin. J. Am. Soc. Nephrol. 3, 1718–1725 (2008)

    Article  PubMed  CAS  Google Scholar 

  27. E.M. El-Shafey, A.E. Alsahow, K. Alsaran, A.A. Sabry, M. Atia, Cinacalcet hydrochloride therapy for secondary hyperparathyroidism in hemodialysis patients. Ther. Apher. Dial. 15(6), 547–555 (2011)

    Article  PubMed  CAS  Google Scholar 

  28. H. Ogata, M. Mizobuchi, F. Koiwa, E. Kinugasa, T. Akizawa, Clinical significance of parathyroid intervention on CKD-MBD management. Nephrol. Dial. Transplant. 1(suppl 3), 9–13 (2008)

    Google Scholar 

  29. G.B. Spasovski, Bone health and vascular calcification relationships in chronic kidney diaease. Int. Urol. Nephrol. 39, 1209–1216 (2007)

    Article  PubMed  CAS  Google Scholar 

  30. G. Conzo, A. Perna, N. Avenia, R.M. De Santo, C.D. Pietra, A. Palazzo et al., Evaluation of the ‘putative’ role of intraoperative intact parathyroid hormone assay during parathyroidectomy for secondary hyperparathyroidism. A retrospective study on 35 consecutive patients. Endocrine (2012). doi:10.1007/s12020-012-9648-5

    Google Scholar 

  31. S. Moe, T. Drueke, J. Cunningham, W. Goodman, K. Martin, K. Olgaard et al., Definition, evaluation, and classification of renal osteodystrophy: a position statemen from kidney disease: improving global outcomes (KDIGO). Kidney Int. 69, 1945–1953 (2006)

    Article  PubMed  CAS  Google Scholar 

  32. G. Jean, C. Chazot, B. Charra, 12 months cinacalcet therapy in hemodialysis patients with secondary hyperparathyroidism: effect on bone markers. Clin. Nephrol. 68(1), 63–64 (2007)

    PubMed  CAS  Google Scholar 

  33. S.J. Steddon, S.L.S. Fan, J. Cuuningham, New prospects for the management of renal bone disease. Nephron Clin. Prac. 99, 1–7 (2005)

    Article  Google Scholar 

  34. Y.H.H. Lien, A.L. Silva, D. Whittman, Effect of cinacalcet on bone mineral density in patients with secondary hyperparathyroidism. Nephrol. Dial. Transplant. 20, 1232–1237 (2005)

    Article  PubMed  CAS  Google Scholar 

  35. A. Yajima, T. Akizama, Y. Tsukamoto, S. Kurihara, A. Ito, K Study Group: impact of cinacalcet hydrochloride on bone histology in patients with secondary hyperparathyroidism. Ther. Apher. Dial. 12(suppl 1), S38–S43 (2008)

    Article  PubMed  CAS  Google Scholar 

  36. J. Muscheites, M. Wigger, E. Drueckler, D.C. Fischer, G. Kundt, D. Haffner, Cinacalcet for secondary hyperparathyroidism in children with end-stage renal disease. Pediatr. Nephrol. 23, 1823–1829 (2008)

    Article  PubMed  Google Scholar 

  37. H. Komaba, S. Nakanishi, A. Fujimori, M. Tanaka, J. Shin, K. Shibuya et al., Cinacalcet effectively reduces parathyroid hormone secretion and gland volume regardless of pretreatment Gland Size in Patients with Secondary Hyperparathyroidism. Clin. J. Am. Soc. Nephrol. 5, 2305–2314 (2010)

    Article  PubMed  CAS  Google Scholar 

  38. L.H. Duntas, N. Stathatos, Cinacalcet as alternative treatment for primary hyperparathyroidism: achievements and prospects. Endocrine 39, 199–204 (2011)

    Article  PubMed  CAS  Google Scholar 

  39. N. Nagano, Pharmacological and clinical properties of calcimimetics: calcium receptor activators that afford an innovative approach to controlling hyperparathyroidism. Pharmacol. Ther. 109(3), 339–365 (2006)

    Article  PubMed  CAS  Google Scholar 

  40. M. Peacock, M.A. Bolognese, M. Brofsky, S. Scumpia, L.R. Sterling, S. Cheng et al., Cinacalcet treatment of primary hyperparathyroidism: biochemical and bone densitometric outcomes in a five-year study. J. Clin. Endocrinol. Metab. 94(12), 4860–4867 (2009)

    Article  PubMed  CAS  Google Scholar 

  41. M. Peacock, J.P. Bilezikian, M.A. Bolonese, M. Brofsky, S. Scumpia, L.R. Sterling et al., Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J. Clin. Endocrinol. Metab. 96(1), E9–E18 (2011)

    Article  PubMed  CAS  Google Scholar 

  42. J.F. Raposo, A. Pires, H. Yokota, H.G. Ferreira, A mathematical model of calcium and phosphorus metabolism in two forms of hyperparathyroidism. Endocrine 41, 309–319 (2012)

    Article  PubMed  CAS  Google Scholar 

  43. M. Eandi, L. Pradelli, S. Iannazzo, S. Chiroli, G. Pontoriero, Economic evaluation of cinacalcet in the treatment of secondary hyperparathyroidism in Italy. Pharmaconomics 28(11), 1041–1054 (2010)

    Article  Google Scholar 

  44. R. Garside, M. Pitt, R. Anderson, S. Mealing, R.D. Souza, K. Sein, The cost-utility of cinacalcet in addition to standard care compared to standard care alone for secondary hyperparathyroidism in end-stage renal disease: a UK perspective. Nephrol. Dial. Transplant. 22, 1428–1436 (2007)

    Article  PubMed  Google Scholar 

  45. R. Boer, A.M. Lalla, V. Belozeroff, Cost-effectiveness of cinacalcet in secondary hyperparathyroidism in the United States. J. Med. Econ. (2012). doi:10.3111/13696998.2012.664799

    PubMed  Google Scholar 

Download references

Acknowledgments

This research received a research grant from Natural Science Foundation of China (No. 81170688). All authors have no conflict of financial interest.

Author information

Authors and Affiliations

  1. Department of Nephrology, The Affiliated Hospital of Qingdao University Medical College, No. 16 Jiangsu Road, The Southern Direct, Qingdao City, Shandong Province, China

    Dan Li, Leping Shao, Haiyan Zhou, Wei Jiang, Wei Zhang & Yan Xu

Authors
  1. Dan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Leping Shao
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Haiyan Zhou
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Wei Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Wei Zhang
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Yan Xu
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yan Xu.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Li, D., Shao, L., Zhou, H. et al. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis. Endocrine 43, 68–77 (2013). https://doi.org/10.1007/s12020-012-9711-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s12020-012-9711-2

Keywords

Search

Navigation